EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 6-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY

被引：1
|
作者：
Correll, Christoph [1 ]
Goldman, Robert [2 ]
Tocco, Michael [2 ]
Pikalov, Andrei [2 ]
Hsu, Jay [2 ]
Loebel, Antony [2 ]
机构：
[1] Hofstra North Shore LIJ Sch Med, Zucker Hillside Hosp, Hempstead, NY USA
[2] Sunovion Pharmaceut Inc, Marlborough, MA USA
来源：
SCHIZOPHRENIA BULLETIN | 2019年 / 45卷
关键词：
D O I：
10.1093/schbul/sbz018.518
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
F106
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [21] The Efficacy and Safety of Lurasidone in Adolescent Patients With Schizophrenia: A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Study
    Correll, Christoph U.
    Goldman, Robert
    Silva, Robert
    Cucchiaro, Josephine
    Deng, Ling
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S597 - S598
  • [22] Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
    Nasrallah, Henry A.
    Cucchiaro, Josephine B.
    Mao, Yongcai
    Pikalov, Andrei A.
    Loebel, Antony D.
    CNS SPECTRUMS, 2015, 20 (02) : 140 - 147
  • [23] Remission and recovery in lurasidone-treated patients with bipolar depression: post-hoc analysis of a 6-week, placebo-controlled trial followed by a 6-month extension
    Loebel, A.
    Siu, C.
    Rajagopalan, K.
    Pikalov, A.
    Cucchiaro, J.
    Ketter, T.
    BIPOLAR DISORDERS, 2015, 17 : 92 - 92
  • [24] Remission in Lurasidone-treated Patients with Bipolar I Depression: Post-hoc Analysis of a 6-week, Placebo-controlled Trial Followed by a 6-month Extension
    Loebel, A.
    Siu, C.
    Pikalov, A.
    Rajagopalan, K.
    Cucchiaro, J.
    Ketter, T.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [25] Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study
    Tsai, Joyce
    Thase, Michael E.
    Mao, Yongcai
    Ng-Mak, Daisy
    Pikalov, Andrei
    Loebel, Antony
    CNS SPECTRUMS, 2017, 22 (02) : 236 - 245
  • [26] EFFICACY AND SAFETY OF BLONANSERIN ORAL TABLET (DSP-5423) IN ADOLESCENTS WITH SCHIZOPHRENIA: A 6-WEEK, RANDOMIZED PLACEBO-CONTROLLED STUDY
    Saito, Takuya
    Ishigaoka, Jun
    Nakamura, Hiroshi
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2020, 59 (10): : S265 - S265
  • [27] Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Kryzhanovskaya, Ludmila
    Schulz, S. Charles
    McDougle, Christopher
    Frazier, Jean
    Dittmann, Ralf
    Robertson-Plouch, Carol
    Bauer, Theresa
    Xu, Wen
    Wang, Wei
    Carlson, Janice
    Tohen, Mauricio
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (01): : 60 - 70
  • [28] Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies
    Calisti, Fabrizio
    Cattaneo, Agnese
    Calabrese, Mariangela
    Mao, Yongcai
    Tocco, Michael
    Pikalov, Andrei
    Goldman, Robert
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (05) : 215 - 222
  • [29] Symptomatic and Functional Remission and Recovery in Lurasidone-treated Patients with Bipolar Depression: Post-hoc Analysis of a 6-week, Placebo-Controlled Trial Followed by a 6-Month Extension
    Loebel, Antony
    Siu, Cynthia
    Rajagopalan, Krithika
    Pikalov, Andrei
    Cucchiaro, Josephine
    Ketter, Terence
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S390 - S390
  • [30] Lurasidone in children and adolescents with bipolar depression associated with mixed (Subsyndromal Hypomanic) features: post-hoc analysis of a randomized placebo-controlled trial
    Tocco, M.
    Pikalov, A.
    Siu, C.
    Loebel, A.
    BIPOLAR DISORDERS, 2018, 20 : 66 - 67
12345